{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:49:34Z","timestamp":1792014574930,"version":"4.4.0"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ctrv.2026.103220","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:14:21Z","timestamp":1790723661000},"page":"103220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["\u201cCurrent approaches and emerging strategies in the treatment of ductal carcinoma in situ and premalignant breast lesions\u201d"],"prefix":"10.1016","volume":"150","author":[{"given":"Tommaso","family":"Ruelle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Chiappe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Lanzavecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Fozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Fregatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Del Mastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Poggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ctrv.2026.103220_bb0005","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: an overview","volume":"149","author":"Ferlay","year":"2021","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103220_bb0010","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/annonc\/mdm481","article-title":"European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition\u2014summary document","volume":"19","author":"Perry","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103220_bb0015","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-075498","article-title":"Invasive breast cancer and breast cancer death after non-screen detected ductal carcinoma in situ from 1990 to 2018 in England: population based cohort study","volume":"384","author":"Mannu","year":"2024","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103220_bb0020","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41416-019-0478-6","article-title":"Ductal carcinoma in situ: to treat or not to treat, that is the question","volume":"121","author":"on behalf of the PRECISION team","year":"2019","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103220_bb0025","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1186\/s12885-015-1904-7","article-title":"Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis","volume":"15","author":"Stuart","year":"2015","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103220_bb0030","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.path.2017.09.009","article-title":"Lobular Carcinoma In Situ","volume":"11","author":"Wen","year":"2018","journal-title":"Surg Pathol Clin"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103220_bb0035","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13058-015-0580-5","article-title":"Molecular drivers of lobular carcinoma in situ","volume":"17","author":"Logan","year":"2015","journal-title":"Breast Cancer Res"},{"issue":"24","key":"10.1016\/j.ctrv.2026.103220_bb0040","doi-asserted-by":"crossref","first-page":"5534","DOI":"10.1200\/JCO.2005.04.038","article-title":"Bilateral risk for subsequent breast Cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data","volume":"23","author":"Chuba","year":"2005","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103220_bb0045","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1002\/cncr.20273","article-title":"Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma","volume":"100","author":"Shelley Hwang","year":"2004","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103220_bb0050","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000319624","article-title":"Early breast Cancer precursor lesions: lessons learned from molecular and clinical studies","volume":"5","author":"Sinn","year":"2010","journal-title":"Breast Care"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103220_bb0055","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1158\/1940-6207.CAPR-13-0222","article-title":"Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study","volume":"7","author":"Hartmann","year":"2014","journal-title":"Cancer Prev Res"},{"issue":"500","key":"10.1016\/j.ctrv.2026.103220_bb0060","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.21614\/chirurgia.116.5.suppl.S97","article-title":"Systemic treatment of ductal carcinoma in situ of the breast","volume":"116","author":"Crimini","year":"2021","journal-title":"Chirurgia (Bucur)"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103220_bb0065","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/his.14091","article-title":"The 2019 World Health Organization classification of tumours of the breast","volume":"77","author":"Tan","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.ctrv.2026.103220_bb0070","series-title":"Rosen\u2019s breast pathology","author":"Hoda","year":"2021"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103220_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17101634","article-title":"Influence of cancerization of lobules in ductal carcinoma in situ of the breast on the pathological outcomes in mastectomy specimens","volume":"17","author":"Alloush","year":"2025","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103220_bb0080","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2267::AID-CNCR13>3.0.CO;2-V","article-title":"A prognostic index for ductal carcinoma in situ of the breast","volume":"77","author":"Silverstein","year":"1996","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103220_bb0085","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10549-025-07768-6","article-title":"Prediction of upstaging in DCIS: the dominant role of pathological over imaging risk factors","volume":"213","author":"Choi","year":"2025","journal-title":"Breast Cancer Res Treat"},{"issue":"10445","key":"10.1016\/j.ctrv.2026.103220_bb0090","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1016\/S0140-6736(24)00425-2","article-title":"Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment","volume":"403","author":"Delaloge","year":"2024","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103220_bb0095","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1159\/000524879","article-title":"AGO recommendations for the diagnosis and treatment of patients with early breast Cancer: update 2022","volume":"17","author":"Ditsch","year":"2022","journal-title":"Breast Care"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103220_bb0100","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jamasurg.2015.0876","article-title":"Survival benefit of breast surgery for low-grade ductal carcinoma in situ: a population-based cohort study","volume":"150","author":"Sagara","year":"2015","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ctrv.2026.103220_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1467738","article-title":"Exploring non-surgical alternatives for low to intermediate-grade in situ ductal carcinoma of the breast using vacuum-assisted excision: the VACIS protocol","volume":"11","author":"Nicosia","year":"2024","journal-title":"Front Med"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103220_bb0110","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.breast.2009.04.003","article-title":"Post-operative radiotherapy for ductal carcinoma in situ of the breast \u2013 a systematic review of the randomised trials","volume":"18","author":"Goodwin","year":"2009","journal-title":"Breast"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103220_bb0115","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/s41416-021-01496-6","article-title":"Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast","volume":"125","author":"Van Seijen","year":"2021","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103220_bb0120","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/jnci\/djr027","article-title":"Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS","volume":"103","author":"Wapnir","year":"2011","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103220_bb0125","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaoncol.2015.2510","article-title":"Breast Cancer mortality after a diagnosis of ductal carcinoma in situ","volume":"1","author":"Narod","year":"2015","journal-title":"JAMA Oncol"},{"issue":"32","key":"10.1016\/j.ctrv.2026.103220_bb0130","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1200\/JCO.2013.49.5077","article-title":"Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial","volume":"31","author":"Donker","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103220_bb0135","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1002\/cncr.10451","article-title":"Breast ductal carcinoma in situ with microinvasion: a definition supported by a long-term study of 1248 serially sectioned ductal carcinomas","volume":"94","author":"De Mascarel","year":"2002","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103220_bb0140","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1002\/(SICI)1097-0142(19971101)80:9<1798::AID-CNCR15>3.0.CO;2-0","article-title":"Consensus conference on the classification of ductal carcinoma in situ","volume":"80","author":"The Consensus Conference Committee","year":"1997","journal-title":"Cancer"},{"issue":"32","key":"10.1016\/j.ctrv.2026.103220_bb0145","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1200\/JCO.2009.21.8560","article-title":"Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the eastern cooperative oncology group","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.ctrv.2026.103220_bb0150","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1200\/JCO.2007.14.2364","article-title":"American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast Cancer","volume":"25","author":"Harris","year":"2007","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.ctrv.2026.103220_bb0155","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1200\/JCO.2015.60.8588","article-title":"Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study","volume":"33","author":"Solin","year":"2015","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.ctrv.2026.103220_bb0160","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1200\/JCO.21.01083","article-title":"Randomized phase III trial evaluating radiation following surgical excision for good-risk ductal carcinoma in situ: long-term report from NRG oncology\/RTOG 9804","volume":"39","author":"McCormick","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103220_bb0165","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2014.57.9029","article-title":"RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation","volume":"33","author":"McCormick","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103220_bb0170","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/cncr.30972","article-title":"Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ","volume":"124","author":"Shurell","year":"2018","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103220_bb0175","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.ijrobp.2011.11.025","article-title":"Five year outcome of 145 patients with ductal carcinoma in situ (DCIS) after accelerated breast radiotherapy","volume":"83","author":"Ciervide","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103220_bb0180","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.clbc.2012.04.006","article-title":"Clinical outcomes using accelerated partial breast irradiation in patients with ductal carcinoma in situ","volume":"12","author":"Shah","year":"2012","journal-title":"Clin Breast Cancer"},{"issue":"10350","key":"10.1016\/j.ctrv.2026.103220_bb0185","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0140-6736(22)01246-6","article-title":"Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3\u201307\/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study","volume":"400","author":"Chua","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103220_bb0190","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.brachy.2017.09.004","article-title":"The American brachytherapy society consensus statement for accelerated partial-breast irradiation","volume":"17","author":"Shah","year":"2018","journal-title":"Brachytherapy"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103220_bb0195","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.prro.2023.11.001","article-title":"Partial breast irradiation for patients with early-stage invasive breast Cancer or ductal carcinoma in situ: an ASTRO clinical practice guideline","volume":"14","author":"Shaitelman","year":"2024","journal-title":"Pract Radiat Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103220_bb0200","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S1470-2045(06)70765-3","article-title":"Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the rare Cancer network","volume":"7","author":"Omlin","year":"2006","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103220_bb0205","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.radonc.2015.01.001","article-title":"The role of boost and hypofractionation as adjuvant radiotherapy in patients with DCIS: a meta-analysis of observational studies","volume":"114","author":"Nilsson","year":"2015","journal-title":"Radiother Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103220_bb0210","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1245\/s10434-021-09903-1","article-title":"The clinical utility of DCISionRT\u00ae on radiation therapy decision making in patients with ductal carcinoma in situ following breast-conserving surgery","volume":"28","author":"Shah","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103220_bb0215","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/jnci\/djaa179","article-title":"21-gene assay and breast Cancer mortality in ductal carcinoma in situ","volume":"113","author":"Rakovitch","year":"2021","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"9472","key":"10.1016\/j.ctrv.2026.103220_bb0220","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","year":"2005","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103220_bb0225","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1053\/j.seminoncol.2015.07.006","article-title":"Ongoing use of data and specimens from National Cancer Institute\u2013sponsored cancer prevention clinical trials in the Community Clinical Oncology Program","volume":"42","author":"Minasian","year":"2015","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ctrv.2026.103220_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(99)05036-9","article-title":"Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial","volume":"353","author":"Fisher","year":"1999","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103220_bb0235","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(10)70266-7","article-title":"Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK\/ANZ DCIS trial","volume":"12","author":"Cuzick","year":"2011","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103220_bb0240","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1200\/JCO.2010.34.0141","article-title":"Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor\u2013positive ductal carcinoma in situ: a study based on NSABP protocol B-24","volume":"30","author":"Allred","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103220_bb0245","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.radonc.2011.02.005","article-title":"Tamoxifen added to radiotherapy and surgery for the treatment of ductal carcinoma in situ of the breast: a meta-analysis of 2 randomized trials","volume":"100","author":"Petrelli","year":"2011","journal-title":"Radiother Oncol"},{"issue":"17","key":"10.1016\/j.ctrv.2026.103220_bb0250","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1200\/JCO.22.02900","article-title":"Randomized placebo controlled trial of low-dose tamoxifen to prevent recurrence in breast noninvasive neoplasia: a 10-year follow-up of TAM-01 study","volume":"41","author":"Lazzeroni","year":"2023","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ctrv.2026.103220_bb0255","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1200\/JCO.18.01779","article-title":"Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia","volume":"37","author":"DeCensi","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103220_bb0260","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-26-00841","article-title":"Low-dose tamoxifen in noninvasive breast neoplasia: long-term results from an individual-participant data pooled analysis","author":"Gandini","year":"2026","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.ctrv.2026.103220_bb0265","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1056\/NEJMoa052258","article-title":"A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer","volume":"353","year":"2005","journal-title":"N Engl J Med"},{"issue":"10021","key":"10.1016\/j.ctrv.2026.103220_bb0270","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0140-6736(15)01129-0","article-title":"Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial","volume":"387","author":"Forbes","year":"2016","journal-title":"Lancet"},{"issue":"10021","key":"10.1016\/j.ctrv.2026.103220_bb0275","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(15)01168-X","article-title":"Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial","volume":"387","author":"Margolese","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103220_bb0280","series-title":"Re-Operating Reconsidered: Surgeries to Improve Margin Status May be Unnecessary for Some Patients with DCIS","author":"Grutman","year":"2026"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103220_bb0285","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/jnci\/djy220","article-title":"Cancer outcomes in DCIS patients without Locoregional treatment","volume":"111","author":"Ryser","year":"2019","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103220_bb0290","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1001\/jama.2024.26698","article-title":"Active monitoring with or without endocrine therapy for low-risk ductal carcinoma in situ: the COMET randomized clinical trial","volume":"333","author":"Hwang","year":"2025","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103220_bb0295","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/jamaoncol.2024.6556","article-title":"Patient-reported outcomes for low-risk ductal carcinoma in situ: a secondary analysis of the COMET randomized clinical trial","volume":"11","author":"Partridge","year":"2025","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103220_bb0300","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamasurg.2017.2181","article-title":"Factors associated with underestimation of invasive cancer in patients with ductal carcinoma in situ: precautions for active surveillance","volume":"152","author":"Chavez De Paz Villanueva","year":"2017","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ctrv.2026.103220_bb0305","series-title":"The single-arm confirmatory trial of tamoxifen alone without surgery for low-risk DCIS of the breast with ER-positive HER2-negative (LORETTA trial: JCOG1505)","author":"Iwata","year":"2026"},{"key":"10.1016\/j.ctrv.2026.103220_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2026.116283","article-title":"De-escalating treatment for low-risk ductal carcinoma in situ: early safety of active surveillance without endocrine therapy in the prespecified interim analysis of the LORD-trial* (BOOG 2014-04)","volume":"237","author":"Wesseling","year":"2026","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2026.103220_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2026.116309","volume":"237","author":"Wallis","year":"2026","journal-title":"Eur J Cancer"},{"issue":"33","key":"10.1016\/j.ctrv.2026.103220_bb0320","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1200\/JCO.19.01472","article-title":"Use of endocrine therapy for breast Cancer risk reduction: ASCO clinical practice guideline update","volume":"37","author":"Visvanathan","year":"2019","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.ctrv.2026.103220_bb0325","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/jnci\/dji372","article-title":"Tamoxifen for the prevention of breast Cancer: current status of the National Surgical Adjuvant Breast and bowel project P-1 study","volume":"97","author":"Fisher","year":"2005","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"25","key":"10.1016\/j.ctrv.2026.103220_bb0330","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","article-title":"Exemestane for breast-Cancer prevention in postmenopausal women","volume":"364","author":"Goss","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103220_bb0335","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10549-012-2318-8","article-title":"The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions","volume":"136","author":"Coopey","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103220_bb0340","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/annonc\/mdv590","article-title":"Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis","volume":"27","author":"Smith","year":"2016","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.ctrv.2026.103220_bb0345","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1200\/JCO.2009.27.8077","article-title":"Patient decisions about breast Cancer chemoprevention: a systematic review and Meta-analysis","volume":"28","author":"Ropka","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103220_bb0350","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1158\/1940-6207.CAPR-17-0162","article-title":"A survey among breast Cancer specialists on the low uptake of therapeutic prevention with tamoxifen or Raloxifene","volume":"11","author":"Noonan","year":"2018","journal-title":"Cancer Prev Res (Phila)"},{"issue":"23","key":"10.1016\/j.ctrv.2026.103220_bb0355","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1200\/JCO.2016.71.7439","article-title":"Participant-reported symptoms and their effect on long-term adherence in the international breast Cancer intervention study I (IBIS I)","volume":"35","author":"Smith","year":"2017","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.ctrv.2026.103220_bb0360","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/jnci\/91.18.1541","article-title":"Validation studies for models projecting the risk of invasive and Total breast Cancer incidence","volume":"91","author":"Costantino","year":"1999","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"23","key":"10.1016\/j.ctrv.2026.103220_bb0365","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1200\/JCO.2009.26.8847","article-title":"Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ","volume":"28","author":"Rudloff","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103220_bb0370","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1634\/theoncologist.2015-0310","article-title":"Tamoxifen initiation after ductal carcinoma in situ","volume":"21","author":"Nichols","year":"2016","journal-title":"Oncologist"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226001349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226001349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:12:29Z","timestamp":1792012349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226001349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":74,"alternative-id":["S0305737226001349"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103220","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cCurrent approaches and emerging strategies in the treatment of ductal carcinoma in situ and premalignant breast lesions\u201d","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103220","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103220"}}